Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Fineline Cube Jun 8, 2026
Company Deals

Junshi Biosciences Forms Strategic JV with Zhiyu Biomedicine, Contributing Oncology Antibody IP and ADC Platform for Multispecific Development

Fineline Cube Jun 8, 2026
Company Deals

Everest Medicines Licenses LNZ100 Presbyopia Treatment from Corxel for Greater China – Aceclidine-Based Eye Drop Offers Novel Miotic Mechanism

Fineline Cube Jun 8, 2026
Company Deals

SSY Group Secures Global Rights to Pediatric Antispasmodic and COPD Drugs from Xinzheng Heying – Full IP Transfer in Category 2.2 and 2.3 Assets

Fineline Cube Jun 5, 2026
Company Deals

Lonza and Stipple Bio Forge Strategic ADC Partnership – Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies

Fineline Cube Jun 5, 2026
Policy / Regulatory

China’s NHC Releases Sixth Pediatric Drug Priority List – 27 Varieties Including Emicizumab, Pembrolizumab, and Omalizumab Targeted for Development

Fineline Cube Jun 5, 2026
Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Fineline Cube Jun 8, 2026
Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Fineline Cube Jun 8, 2026
Company

WuXi AppTec Reports 5.77% YOY Revenue Growth and 31.97% Increase in Net Profits for 2023Q1

Fineline Cube Apr 25, 2023

WuXi AppTec Co., Ltd (SHA: 603259, HKG: 2359) has released its financial report for the...

Company Legal / IP

SMPA Suspends Procurement of Levornidazole by Warrant Pharmaceutical Over IP Concerns

Fineline Cube Apr 25, 2023

Shanghai’s Sunshine Medical Procurement All-in-One (SMPA) has released a notification to suspend the procurement status...

Company Deals

Tot Biopharmaceutical Partners with Suzhou Smart Nuclide on Radioactive Drug Development

Fineline Cube Apr 25, 2023

China-based Tot Biopharmaceutical International Co., Ltd (HKG: 1875) has announced a strategic partnership with Suzhou...

Company Drug

GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14

Fineline Cube Apr 24, 2023

The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of...

Company Drug

Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan

Fineline Cube Apr 24, 2023

China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for...

Company Deals

Grand Pharmaceutical Group to Acquire Majority Stake in BlackSwan Vascular Inc. for $37.5 Million

Fineline Cube Apr 24, 2023

Grand Pharmaceutical Group Limited (HKG: 0512), a China-based pharmaceutical company, has announced plans to acquire...

Company Drug

Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor

Fineline Cube Apr 24, 2023

Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial...

Company Drug

Sichuan Biokin Pharmaceutical Gets NMPA Approval for Two Clinical Studies on Cancer Therapies

Fineline Cube Apr 24, 2023

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced receiving approval...

Company

YiChang HEC ChangJiang Pharmaceutical Reports 309.83% YOY Revenue Growth in 2022 Financials

Fineline Cube Apr 24, 2023

YiChang HEC ChangJiang Pharmaceutical Co., Ltd (HKG: 1558), a China-based pharmaceutical company, has released its...

Company

LianBio Appoints Pascal Qian as COO in Anticipation of Mavacamten Market Launch

Fineline Cube Apr 23, 2023

China-based biotech firm LianBio (OTCMKTS: LIANY) has announced the promotion of its current China General...

Company Deals

Suzhou Basecare Medical and Qitan Tech Partner to Advance Nanopore Sequencing in PGT

Fineline Cube Apr 23, 2023

Suzhou Basecare Medical Co., Ltd (HKG: 2170), a China-based in vitro fertilization (IVF) specialist, has...

Company Drug

Jiangsu Hengrui Pharmaceuticals’ Pyrotinib Gains NMPA Approval for HER2+ Breast Cancer Treatment

Fineline Cube Apr 23, 2023

Jiangsu Hengrui Pharmaceuticals (SHA: 600276), a leading China-based pharmaceutical company, has announced receiving another indication...

Company Drug

Evopoint Biosciences Gets CDE Approval for Phase I/II Study of XNW27011 ADC

Fineline Cube Apr 23, 2023

Suzhou Evopoint Biosciences Co., Ltd., a China-based pharmaceutical company, has announced receiving approval from the...

Hospital Policy / Regulatory

China’s NHC Advances Enhanced Recovery After Surgery (ERAS) Protocols Nationwide

Fineline Cube Apr 23, 2023

The National Health Commission (NHC) has released a notification with the goal of promoting enhanced...

Company Drug

ChengDu ShengNuo Biotech Secures NMPA Approval for Generic Firazyr Equivalent

Fineline Cube Apr 23, 2023

ChengDu ShengNuo Biotech Co., Ltd (SHA: 688117), a China-based polypeptide specialist, has announced that it...

Company Deals

CanSino Biotechnology Leads RMB 500 Million Private Equity Fund for Vaccine Investments

Fineline Cube Apr 23, 2023

China-based vaccines specialist CanSino Biotechnology Inc., (HKG: 6185) has announced plans to invest RMB 140...

Company Deals

PharmaEssentia Corporation Completes Secondary Offering of GDR Shares on Luxembourg Exchange

Fineline Cube Apr 23, 2023

Taiwan-based PharmaEssentia Corporation (TPE: 6446) has announced the successful closing of a secondary offering of...

Company

Lee’s Pharmaceutical Holdings Ltd Reports 2022 Revenues and Pipeline Updates

Fineline Cube Apr 23, 2023

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its 2022 financial report, recording HKD...

Company Drug

Reistone Biopharma’s RSS0343 Receives NMPA Approval for Non-Cystic Fibrosis Bronchiectasis

Fineline Cube Apr 23, 2023

Reistone Biopharma Co., Ltd, a company incubated by Hengrui Pharmaceuticals (SHA: 600276) with an investment...

Company Deals

Siemens Healthineers and China Chest Pain Center Launch Smart Training Program

Fineline Cube Apr 23, 2023

German healthcare giant Siemens Healthineers (ETR: SHL) has partnered with the China Chest Pain Center...

Posts pagination

1 … 546 547 548 … 679

Recent updates

  • PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset
  • Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence
  • Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States
  • Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy
  • Bayer’s Kerendia (Finerenone) Demonstrates Significant Kidney Protection in Non-Diabetic CKD Phase III Trial – First Mineralocorticoid Receptor Antagonist to Show Efficacy Beyond Diabetes Population
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

PegBio Receives $7.8M Milestone Payment from Tenry Pharma for Paidakang GLP-1 Agonist – Chinese Biotech Secures First Commercial Revenue from Type 2 Diabetes Asset

Company Medical Device

Sino Medical Sciences Secures Colombian Approval for HT Supreme Drug-Eluting Stent – Advanced Dual-Polymer Technology Expands Latin American Presence

Company Drug

Henlius Biotech Doses First US Patient in Global Phase I Trial of HLX17 Pembrolizumab Biosimilar – Dual FDA/NMPA Approval Enables Simultaneous Development in China and United States

Company Drug

Novo Nordisk’s CagriSema Fixed-Dose Combination Delivers Superior HbA1c and Weight Loss in Phase 3 REIMAGINE Trials – Amylin/GLP-1 Dual Therapy Outperforms Semaglutide Monotherapy

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.